Lymphoblastic Leukemia, Acute, Childhood Clinical Trial
Official title:
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).
This is a study for pediatric patients with relapsed acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). Some people diagnosed with leukemia have changes in a receptor located on the surface of white blood cells called FLT3. This is known as a FLT3 mutation. FLT3 plays an important role in the way cells grow and divide. In normal cells, the FLT3 receptor is switched off most of the time and only switches on when it gets a chemical signal from outside. But cells with the FLT3 mutation have the grow signal permanently switched on. This means leukemia cells with the FLT3 mutation are growing and dividing all the time. Doctors have found that people with leukemia cells that carry FLT3 mutations are less likely to go into remission with chemotherapy and have a higher risk of the leukemia coming back after treatment. This is a study of an investigational drug called AC220. AC220 is considered investigational because it has not been approved in the United States by the Food and Drug Administration (FDA). AC220 is a drug which is able to "turn off" the FLT3 grow signal. AC220 will be given with cytarabine and etoposide to treat the relapsed leukemia. This is a phase I study, which means that the study is being done to find the highest dose of AC220 that can be given safely with the drugs cytarabine and etoposide to children and young adults. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
| Recruiting |
NCT05495035 -
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
|
Phase 1 | |
| Completed |
NCT00991133 -
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Active, not recruiting |
NCT05440409 -
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
|
||
| Completed |
NCT01861002 -
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
|
Phase 1 | |
| Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
| Completed |
NCT01896752 -
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL
|
N/A | |
| Completed |
NCT01321346 -
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT01614197 -
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05429905 -
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02879643 -
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
|
Phase 1 | |
| Recruiting |
NCT03022747 -
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
|
Phase 2 | |
| Active, not recruiting |
NCT03817320 -
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT05611086 -
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
|
Phase 4 | |
| Terminated |
NCT01186328 -
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
| Completed |
NCT02906371 -
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
|
Phase 1 | |
| Recruiting |
NCT05038696 -
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
|
Phase 1 |